Embecta (NASDAQ:EMBC) CFO Jacob Elguicze Acquires 20,000 Shares of Stock

Embecta Corp. (NASDAQ:EMBC) CFO Jacob Elguicze bought 20,000 shares of Embecta stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $4.67 per share, with a total value of $93,400.00. Following the completion of the transaction, the chief financial officer directly owned 309,139 shares in the company, valued at approximately $1,443,679.13. This trade represents a 6.92% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Embecta Stock Up 7.6%

Shares of EMBC stock opened at $5.11 on Friday. The firm has a market cap of $289.53 million, a P/E ratio of 3.45 and a beta of 0.81. The company has a 50 day moving average of $3.46 and a 200-day moving average of $6.42. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.27 by $0.29. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The business had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. During the same quarter in the prior year, the business earned $1.12 earnings per share. Embecta’s revenue for the quarter was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, equities analysts expect that Embecta Corp. will post 1.84 EPS for the current year.

Embecta Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 27th. Embecta’s dividend payout ratio is currently 2.70%.

Embecta News Roundup

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively bought 70,000 Embecta shares worth approximately $334,200 on August 12. The purchases increased their individual holdings and may signal management confidence that the stock is undervalued. SEC insider transaction filing
• Neutral Sentiment: Several investor-rights firms are reminding shareholders that August 17, 2026, is the deadline to seek appointment as lead plaintiff for investors who purchased EMBC shares between November 25, 2025, and May 4, 2026. These announcements largely repeat the same lawsuit information rather than represent new company operating news. BFA Law class action reminder
• Negative Sentiment: The filed class action alleges that Embecta and certain executives violated federal securities laws by misrepresenting the commercial stability of its insulin pen-needle business and issuing misleading fiscal 2026 guidance. The claims follow a significant stock decline and could create legal costs, reputational damage and additional uncertainty around management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

Wall Street Analysts Forecast Growth

EMBC has been the subject of several recent research reports. BTIG Research lowered Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Mizuho cut their target price on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. Bank of America reduced their target price on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research note on Monday, May 18th. Finally, Weiss Ratings lowered shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Embecta has a consensus rating of “Reduce” and a consensus target price of $11.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its position in shares of Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares during the period. Wexford Capital LP bought a new position in shares of Embecta in the third quarter valued at approximately $94,000. Tower Research Capital LLC TRC grew its stake in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in Embecta during the third quarter valued at approximately $115,000. Finally, One Wealth Advisors LLC bought a new stake in Embecta during the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.